全球气喘生物製药市场规模、份额、趋势和成长分析报告（2026-2034）

预计气喘生物製剂市场将从 2025 年的 99.5 亿美元成长到 2034 年的 293.1 亿美元，2026 年至 2034 年的复合年增长率为 12.76%。

由于重症和难治性气喘病例数量不断增加，全球气喘生物製剂市场正经历强劲成长。生物製剂疗法可针对特定的免疫通路，为对传统疗法无反应的患者提供更佳的治疗效果。人们对先进气喘管理的认识不断提高，以及获得专业医疗服务的途径日益便捷，都推动了市场扩张。

关键成长要素包括单株抗体疗法的进步和临床研究投入的增加。製药公司正致力于采用个人化医疗方法来提高治疗效果。已开发地区医疗保健支出的增加和有利的报销机制正在推动该疗法的普及。此外，诊断技术的进步，尤其是用于识别合格患者的技术，也增强了市场需求。

鑑于对新型生物标的和联合治疗的持续研究，前景十分乐观。新兴市场不断完善的医疗基础设施将为市场开闢新的成长途径。各公司正加大对病患支持计画和创新给药方法的投入。随着精准医疗的不断发展，全球气喘生物製药市场预计将实现持续的长期成长。

目录

第一章：引言

第二章执行摘要

第三章 市场变数、趋势与框架

• 市场谱系展望
• 渗透率和成长前景分析
• 价值链分析
• 法律规范
  • 标准与合规性
  • 监管影响分析
• 市场动态
  • 市场驱动因素
  • 市场限制因素
  • 市场机会
  • 市场挑战
• 波特五力分析
• PESTLE分析

第四章：全球气喘生物製药市场：依药物类别划分

• 市场分析、洞察与预测
• 选择性免疫抑制剂
• 白细胞介素抑制剂
• 其他的

第五章 全球气喘生物製药市场：依通路划分

• 市场分析、洞察与预测
• 零售药房
• 电子商务
• 其他的

第六章 全球气喘生物製药市场：依地区划分

• 区域分析
• 北美市场分析、洞察与预测
  • 我们
  • 加拿大
  • 墨西哥
• 欧洲市场分析、洞察与预测
  • 英国
  • 法国
  • 德国
  • 义大利
  • 俄罗斯
  • 其他欧洲国家
• 亚太市场分析、洞察与预测
  • 印度
  • 日本
  • 韩国
  • 澳洲
  • 东南亚
  • 其他亚太国家
• 拉丁美洲市场分析、洞察与预测
  • 巴西
  • 阿根廷
  • 秘鲁
  • 智利
  • 其他拉丁美洲国家
• 中东和非洲市场分析、洞察与预测
  • 沙乌地阿拉伯
  • UAE
  • 以色列
  • 南非
  • 其他中东和非洲国家

第七章 竞争情势

• 最新趋势
• 公司分类
• 供应链和销售管道合作伙伴（根据现有资讯）
• 市场占有率和市场定位分析（基于现有资讯）
• 供应商情况（基于现有资讯）
• 策略规划

第八章：公司简介

• 主要公司的市占率分析
• 公司简介
  • Amgen Inc
  • AstraZeneca
  • F. Hoffmann-La Roche Ltd
  • GSK Plc
  • Novartis AG
  • Regeneron Pharmaceuticals Inc
  • Sanofi
  • Teva Pharmaceutical Industries Ltd
  • GlaxoSmithKline
  • AstraZeneca Plc

The Asthma Biologics Market size is expected to reach USD 29.31 Billion in 2034 from USD 9.95 Billion (2025) growing at a CAGR of 12.76% during 2026-2034.

The Global Asthma Biologics Market is experiencing robust growth due to increasing prevalence of severe and uncontrolled asthma cases. Biologic therapies target specific immune pathways, offering improved outcomes for patients who do not respond to traditional treatments. Rising awareness about advanced asthma management and improved access to specialty care are supporting market expansion.

Major growth drivers include advancements in monoclonal antibody therapies and growing clinical research investments. Pharmaceutical companies are focusing on personalized medicine approaches to enhance treatment effectiveness. Increasing healthcare spending and supportive reimbursement frameworks in developed regions are boosting adoption. Additionally, improved diagnostic techniques for identifying eligible patients are strengthening demand.

Future prospects appear promising as ongoing research explores new biologic targets and combination therapies. Emerging markets with expanding healthcare infrastructure will create new growth avenues. Companies are investing in patient support programs and innovative delivery methods. As precision medicine continues to evolve, the Global Asthma Biologics Market is expected to witness sustained long-term expansion.

Our reports are meticulously crafted to provide clients with comprehensive and actionable insights into various industries and markets. Each report encompasses several critical components to ensure a thorough understanding of the market landscape:

Market Overview: A detailed introduction to the market, including definitions, classifications, and an overview of the industry's current state.

Market Dynamics: In-depth analysis of key drivers, restraints, opportunities, and challenges influencing market growth. This section examines factors such as technological advancements, regulatory changes, and emerging trends.

Segmentation Analysis: Breakdown of the market into distinct segments based on criteria like product type, application, end-user, and geography. This analysis highlights the performance and potential of each segment.

Competitive Landscape: Comprehensive assessment of major market players, including their market share, product portfolio, strategic initiatives, and financial performance. This section provides insights into the competitive dynamics and key strategies adopted by leading companies.

Market Forecast: Projections of market size and growth trends over a specified period, based on historical data and current market conditions. This includes quantitative analyses and graphical representations to illustrate future market trajectories.

Regional Analysis: Evaluation of market performance across different geographical regions, identifying key markets and regional trends. This helps in understanding regional market dynamics and opportunities.

Emerging Trends and Opportunities: Identification of current and emerging market trends, technological innovations, and potential areas for investment. This section offers insights into future market developments and growth prospects.

MARKET SEGMENTATION

By Drug Class

• Selective Immuno-suppressants
• Interleukin Inhibitors
• Others

By Distribution Channel

• Retail Pharmacies
• E-commerce
• Others

COMPANIES PROFILED

• Amgen Inc, AstraZeneca, F HoffmannLa Roche Ltd, GSK plc, Novartis AG, Regeneron Pharmaceuticals Inc, Sanofi, Teva Pharmaceutical Industries Ltd, GlaxoSmithKline, AstraZeneca plc
• We can customise the report as per your requirements.

TABLE OF CONTENTS

Chapter 1. PREFACE

• 1.1. Market Segmentation & Scope
• 1.2. Market Definition
• 1.3. Information Procurement
  • 1.3.1 Information Analysis
  • 1.3.2 Market Formulation & Data Visualization
  • 1.3.3 Data Validation & Publishing
• 1.4. Research Scope and Assumptions
  • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

• 2.1. Market Snapshot
• 2.2. Segmental Outlook
• 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

• 3.1. Market Lineage Outlook
• 3.2. Penetration & Growth Prospect Mapping
• 3.3. Value Chain Analysis
• 3.4. Regulatory Framework
  • 3.4.1 Standards & Compliance
  • 3.4.2 Regulatory Impact Analysis
• 3.5. Market Dynamics
  • 3.5.1 Market Drivers
  • 3.5.2 Market Restraints
  • 3.5.3 Market Opportunities
  • 3.5.4 Market Challenges
• 3.6. Porter's Five Forces Analysis
• 3.7. PESTLE Analysis

Chapter 4. GLOBAL ASTHMA BIOLOGICS MARKET: BY DRUG CLASS 2022-2034 (USD MN)

• 4.1. Market Analysis, Insights and Forecast Drug Class
• 4.2. Selective Immuno-suppressants Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.3. Interleukin Inhibitors Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.4. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 5. GLOBAL ASTHMA BIOLOGICS MARKET: BY DISTRIBUTION CHANNEL 2022-2034 (USD MN)

• 5.1. Market Analysis, Insights and Forecast Distribution Channel
• 5.2. Retail Pharmacies Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.3. E-commerce Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.4. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 6. GLOBAL ASTHMA BIOLOGICS MARKET: BY REGION 2022-2034(USD MN)

• 6.1. Regional Outlook
• 6.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 6.2.1 By Drug Class
  • 6.2.2 By Distribution Channel
  • 6.2.3 United States
  • 6.2.4 Canada
  • 6.2.5 Mexico
• 6.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 6.3.1 By Drug Class
  • 6.3.2 By Distribution Channel
  • 6.3.3 United Kingdom
  • 6.3.4 France
  • 6.3.5 Germany
  • 6.3.6 Italy
  • 6.3.7 Russia
  • 6.3.8 Rest Of Europe
• 6.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 6.4.1 By Drug Class
  • 6.4.2 By Distribution Channel
  • 6.4.3 India
  • 6.4.4 Japan
  • 6.4.5 South Korea
  • 6.4.6 Australia
  • 6.4.7 South East Asia
  • 6.4.8 Rest Of Asia Pacific
• 6.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 6.5.1 By Drug Class
  • 6.5.2 By Distribution Channel
  • 6.5.3 Brazil
  • 6.5.4 Argentina
  • 6.5.5 Peru
  • 6.5.6 Chile
  • 6.5.7 South East Asia
  • 6.5.8 Rest of Latin America
• 6.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 6.6.1 By Drug Class
  • 6.6.2 By Distribution Channel
  • 6.6.3 Saudi Arabia
  • 6.6.4 UAE
  • 6.6.5 Israel
  • 6.6.6 South Africa
  • 6.6.7 Rest of the Middle East And Africa

Chapter 7. COMPETITIVE LANDSCAPE

• 7.1. Recent Developments
• 7.2. Company Categorization
• 7.3. Supply Chain & Channel Partners (based on availability)
• 7.4. Market Share & Positioning Analysis (based on availability)
• 7.5. Vendor Landscape (based on availability)
• 7.6. Strategy Mapping

Chapter 8. COMPANY PROFILES OF GLOBAL ASTHMA BIOLOGICS INDUSTRY

• 8.1. Top Companies Market Share Analysis
• 8.2. Company Profiles
  • 8.2.1 Amgen Inc
  • 8.2.2 AstraZeneca
  • 8.2.3 F. Hoffmann-La Roche Ltd
  • 8.2.4 GSK Plc
  • 8.2.5 Novartis AG
  • 8.2.6 Regeneron Pharmaceuticals Inc
  • 8.2.7 Sanofi
  • 8.2.8 Teva Pharmaceutical Industries Ltd
  • 8.2.9 GlaxoSmithKline
  • 8.2.10 AstraZeneca Plc